New pill could help restore skin color in vitiligo patients
NCT ID NCT07625891
First seen Jun 24, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This study tests an experimental drug called D-2570 in 160 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take either D-2570 or a placebo pill once daily for 24 weeks, with an optional 24-week extension. The goal is to see if the drug safely helps bring back skin color, especially on the face.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- D-2570 (an oral drug taken as a pill once daily)
- What this could lead to
- If successful, this could point toward a new daily pill treatment to help restore skin color in people with vitiligo.
- What could go wrong
- This is an early Phase 2 trial with only 160 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Voluntarily signs informed consent and complies with study procedures. * Age 18-65 years, male or female. * Clinical diagnosis of non-segmental vitiligo at screening. * F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo. * Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose. Exclusion Criteria: * \- Segmental, mixed vitiligo or other concurrent pigmentary/active skin disorders interfering with study assessment. * Over 33% facial or total vitiligo lesions with leukotrichia. * Pregnant or breastfeeding females. * Active, latent or inadequately treated tuberculosis infection. * Positive HIV, active HBV/HCV infection, or untreated syphilis. * Current or history of severe herpes infection. * Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment. * Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study. * Uncontrolled thyroid disease, severe cardiovascular/cerebrovascular disease or other unstable severe systemic disorders. * Severe psychiatric disease, suicidal ideation, or alcohol/drug abuse within 6 months. * Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia). * Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing. * Clinically significant abnormal lab results: elevated liver/renal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts. * History of severe drug hypersensitivity or drug-related toxicity. * Any condition that may impair protocol compliance or study participation per investigator judgment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 201203, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an experimental pill help teenagers with vitiligo?
- Can a skin cream bring back color to faces with vitiligo?
- Skin markers may reveal how light therapy fights vitiligo
- Can Real-World data unlock better skin disease care?
- New ointment aims to restore skin color in vitiligo
- Cream-and-Steroid combo aims to recolor vitiligo patches